Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Year: 2026
Type: review
Abstract: The emergence of multi-omics technologies has enabled the integration of genomic, transcriptomic, epigenomic, proteomic, and metabolomic data to characterize the molecular complexity of cancer. Single-cell and spatial profiling further resolve intratumoral heterogeneity, cell-cell interactions, and the microenvironmental determinants of therapeutic responses. In parallel, artificial intelligence (AI) provides computational approaches for integrating these heterogeneous data types across target identification, drug response prediction, toxicity assessment, and drug-combination modeling. Across these domains, the available evidence indicates that multi-omics integration is most beneficial when the included layers provide complementary biological information; that single-cell and spatial omics analyses reveal treatment-resistant populations and niches but remain largely research-grade and thus not ready for routine clinical deployment; and that although foundation models support some representation-learning tasks, their advantages in perturbation-response prediction require confirmation via stringent evaluation. By distinguishing externally validated advances from retrospective proof-of-concept studies, we provide a practical framework for evaluating the translational readiness of AI-driven multi-omics tools in precision oncology.
Source: Acta Pharmacologica Sinica
Language: English
Subfield: Drug Discovery
Domain: Life Sciences
Keywords: artificial intelligence, multi-omics integration, anticancer drug discovery, drug synergy, target identification, drug response prediction, toxicity prediction, single-cell omics, spatial omics, intratumoral heterogeneity, treatment resistance, precision oncology, foundation models, translational readiness
Open Access status: hybrid
Estimated APC paid: $4,390
OpenAlex ID: W7234418845
